Beam Therapeutics Inc
BEAM
View Detailed Chart
16.860USD
+0.220+1.32%
Close 08/27, 16:00（ET）Quotes delayed by 15 min
1.70BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.32%
5 Days
+3.12%
1 Month
-22.38%
6 Months
-37.81%
Year to Date
-32.02%
1 Year
-37.81%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-08-26Key Insights
The company's fundamentals are relatively very healthy.Its valuation is considered fairly valued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Buy.The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analysts' Target
Based on
16
analysts
Buy
Current Rating
44.846
Target Price
+169.51%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Growing
The company is in a growing phase, with the latest annual income totaling USD 63.52M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 30.32.
Overvalued
The company’s latest PE is -3.71, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 101.17M shares, increasing 10.48% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 10.41M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Ticker SymbolBEAM
CompanyBeam Therapeutics Inc
CEOMr. John M. Evans
Websitehttps://beamtx.com/
Related Instruments
-0.02%
+2.33%
+0.52%
-2.84%
+1.79%
-1.70%
-8.06%
+1.30%
+0.89%
-4.02%
-1.86%
-1.76%
+0.44%
+0.05%
+1.94%
+1.30%
-1.00%
0.00%
-0.61%
+2.05%
